1.Endometrial carcinoma diagnosed after hysterectomy
Journal of Chinese Physician 2015;17(8):1121-1123
The clinical manifestation of endometrial uterine cancers is similar to other gynecological diseases like endometrial hyperplasia,polyps,uterine myoma,and adenomyosis.This similarity may result in missed diagnosis of endometrial cancer,which should be paid wide attention.In these cases,pathological examination reports malignancy of uterine specimen after simple hysterectomy.Personalized treatment,such as observation and reoperation,should be supplemented for these patients,according to the pathological characteristics of the tumor,risk factors of lymphatic and ovarian metastasis and the willingness of patient.
2.Investigation of occupational hazard emergencies in power grid enterprises in three regions from 2018 to 2020
Xinyu WANG ; Quanquan GONG ; Ranyi DING ; Lianke XIE ; Dandan DOU ; Kun WANG ; Shengfeng WANG
China Occupational Medicine 2023;50(1):53-56
3. Chain-mediated effects of resilience and ruminant meditation on post-gastrectomy stress perception and post-traumatic growth in postoperative patients with gastric cancer
Xinyu DOU ; Shoulin ZHU ; Xiaomin ZHOU
Chinese Journal of Practical Nursing 2020;36(6):424-429
Objective:
To analyze the correlation between pressure perception, psychological resilience, ruminant meditation and post-traumatic growth in postoperative patients with gastric cancer after gastrectomy.
Methods:
Totally 384 patients with gastric cancer who underwent total gastrectomy or subtotal gastrectomy from January 2015 to January 2018 in 6 major hospitals in Lianyungang were selected as the subjects,who are measured at pressure perception, post-traumatic growth, post-traumatic growth and event-related ruminative.
Results:
In postoperative patients with gastric cancer, ruminant meditation and psychological resilience all partially had mediation effect between pressure perception and post-traumatic growth (
4.Improvement effect and mechanism of matrine on experimental autoimmune encephalomyelitis mice
Xinyu LI ; Yaojuan CHU ; Mengmeng DOU ; Rui MA ; Silu LI ; Lin ZHU
China Pharmacy 2023;34(10):1177-1181
OBJECTIVE To investigate whether matrine exerts improvement effect on experimental autoimmune encephalomyelitis (EAE) mice by regulating ferroptosis pathway. METHODS Totally 30 female C57BL/6 mice were randomly assigned into normal group, model group and matrine group, with 10 mice in each group. Model group and matrine group were given antigen emulsion containing inactivated Mycobacterium tuberculosis and MOG35-55 to induce EAE model. Matrine group was injected with Matrine injection (50 mg/kg) intraperitoneally since the 7th day after immunization; normal group and model group were given constant volume of normal saline intraperitoneally, once a day, since 18th day after immunization. The neurofunctional score of mice was recorded, and hematoxylin and eosin staining and Luxol fast blue staining were used to observe inflammatory cell infiltration and demyelination in spinal cord tissue. The quantitative reverse transcription PCR and Western blot assay were performed to determine the mRNA expressions of transferrin receptor 1 (TFR1), nuclear receptor coactivator 4 (NCOA4) and hephaestin (Heph), and the protein expressions of system Xc- (xCT) and glutathione peroxidase 4 (GPx4). RESULTS Compared with normal group, accumulative neurofunctional score was significantly increased in model group (P<0.01); inflammatory cell infiltration and demyelination were obvious in spinal cord tissue, and related scores were increased significantly (P<0.01). The mRNA expressions of TFR1 and NCOA4 in myelin tissue were up-regulated significantly, while the mRNA expression of Heph and the protein expressions of xCT and GPx4 were down-regulated significantly (P<0.05 or P<0.01). Compared with model group, above indexes of matrine group were all improved significantly (P<0.05 or P<0.01). CONCLUSIONS Matrine can improve EAE mice, the mechanism of which may be associated with regulating iron metabolism pathway and xCT/GPx4 pathway in ferroptosis.
5.Establishment and evaluation of anterior cervical discectomy fusion model in small-tailed Han sheep model
Xinyu DOU ; Yu LIU ; Xiao LIU ; Bin ZHU ; Fei JIA ; Linbang WANG ; Gong JIN ; Fei SHEN ; Xiaoguang LIU
Acta Laboratorium Animalis Scientia Sinica 2024;32(2):139-150
Objective Cervical disc herniation(CDH)is one of the common orthopaedic diseases.With the in-depth study of it and the development of cervical implants,the establishment of cervical fusion animal models has become an indispensable part.Notably however,studies of the establishment and evaluation of cervical fusion animal models in China are currently lacking.This study aimed to provide a suitable animal model and evaluation scheme for implants for cervical spine-related research.Methods Small-tailed Han sheep were chosen for anterior cervical discectomy fusion(ACDF)after modified surgery,and a polyetheretherketone(PEEK)interbody fusion cage(Cage)(control group),3D-printed Ti6Al4V Cage(group 1),and new method Ti6Al4V Cage(group 2)were implanted in different cervical segments(C2/3~C4/5)in each sheep,respectively.Hematology and histopathological analyses were carried out after surgery to evaluate recovery of sheep and the biosafety of the materials.Bone in-growth and bone fusion were assessed by X-ray,computed tomography(CT),Micro-CT and quantitative analysis,hard tissue section staining,and biomechanical tests.Results The modified ACDF ovine model was established successfully.There were no significant differences in important hematology indexes(P>0.05)and histopathological analysis showed no pathological changes,such as inflammatory cell infiltration.The implants had good biosafety.Furthermore,X-ray and CT examinations showed that the position of internal fixation and the interbody fusion were good.Micro-CT and quantitative analysis at 3 and 6 months after operation showed that compared with PEEK Cage group,the bone volume/total volume and trabecular number were significantly increased(P<0.01)while the trabecular spacing was significantly decreased in the new method Ti6Al4V and 3D-printed Ti6Al4V groups compared with the PEEK Cage group(P<0.01).Moreover,the new method new method Ti6Al4V Cage group had more bone growth(P<0.01).Hard tissue section staining demonstrated that the pores of the new method Ti6Al4V Cage and 3D-printed Ti6Al4V Cage had obvious bone growth and relatively dense pores in the new method Ti6Al4V and 3D-printed Ti6Al4V groups,and the combination was slightly better than that of PEEK Cage.Biomechanical evaluation indicated that the new method Ti6Al4V Cage and 3D-printed Ti6Al4V Cage reduced the range of cervical flexion-extension,lateral bending,and axial rotation(P<0.05)compared with the PEEK cage,as well as enhancing the stability of the cervical vertebra,and the new method Ti6Al4 V Cage was more advantageous(P<0.05).Conclusions After the establishment of the modified ACDF ovine model,reasonable and effective assessment method were used to demonstrate the suitability and effectiveness of the model and the good biosecurity of all three Cage materials.Compared with the PEEK Cage,the new method Ti6Al4V Cage and 3D-printed Ti6Al4V Cages showed better performances in terms of bone growth and bone fusion,which could enhance the stability of the cervical vertebrae.The new method Ti6Al4V Cage was particularly advantageous.
6.Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Chengyuan GU ; Zengjun WANG ; Tianxin LIN ; Zhiyu LIU ; Weiqing HAN ; Xuhui ZHANG ; Chao LIANG ; Hao LIU ; Yang YU ; Zhenzhou XU ; Shuang LIU ; Jingen WANG ; Linghua JIA ; Xin YAO ; Wenfeng LIAO ; Cheng FU ; Zhaohui TAN ; Guohua HE ; Guoxi ZHU ; Rui FAN ; Wenzeng YANG ; Xin CHEN ; Zhizhong LIU ; Liqiang ZHONG ; Benkang SHI ; Degang DING ; Shubo CHEN ; Junli WEI ; Xudong YAO ; Ming CHEN ; Zhanpeng LU ; Qun XIE ; Zhiquan HU ; Yinhuai WANG ; Hongqian GUO ; Tiwu FAN ; Zhaozhao LIANG ; Peng CHEN ; Wei WANG ; Tao XU ; Chunsheng LI ; Jinchun XING ; Hong LIAO ; Dalin HE ; Zhibin WU ; Jiandi YU ; Zhongwen FENG ; Mengxiang YANG ; Qifeng DOU ; Quan ZENG ; Yuanwei LI ; Xin GOU ; Guangchen ZHOU ; Xiaofeng WANG ; Rujian ZHU ; Zhonghua ZHANG ; Bo ZHANG ; Wanlong TAN ; Xueling QU ; Hongliang SUN ; Tianyi GAN ; Dingwei YE
Chinese Medical Journal 2023;136(10):1207-1215
BACKGROUND:
LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.
METHODS:
We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels.
RESULTS:
On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]).
CONCLUSION:
LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT04563936.
Humans
;
Male
;
Antineoplastic Agents, Hormonal/therapeutic use*
;
East Asian People
;
Gonadotropin-Releasing Hormone/agonists*
;
Goserelin/therapeutic use*
;
Prostate-Specific Antigen
;
Prostatic Neoplasms/drug therapy*
;
Testosterone